PCSK9 inhibitor to protect against inflammation after heart bypass surgery
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests whether a drug called a PCSK9 inhibitor can reduce harmful inflammation and organ damage in people recovering from coronary artery bypass surgery (CABG). If you are scheduled for bypass surgery within a month, this study may be an option for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a condition that reduces blood flow to the heart (myocardial ischemic syndrome).
- You are scheduled to have coronary artery bypass surgery within the next month.
- You are willing to take part and sign a consent form.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
- You have no history of severe allergic reactions to PCSK9 inhibitors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether starting a cholesterol-lowering drug called a PCSK9 inhibitor soon after a heart attack can help prevent future blockages. If you had a heart attack, received a stent, and have other arteries with minor blockages, this trial may be for you.
This study tests whether starting strong cholesterol-lowering treatment early in the hospital can improve outcomes for people with acute coronary syndrome (a serious heart condition like a heart attack or unstable angina). It may help if you have high LDL cholesterol.
This trial tests whether a PCSK9 inhibitor (a drug that lowers cholesterol) can help people who recently had a stroke caused by narrowing of an artery inside the skull. It aims to see if the drug can prevent more strokes and improve recovery.
This trial studies whether starting a PCSK9-blocking medicine early after a specific type of heart attack can improve heart outcomes. You may be eligible if you have a STEMI heart attack soon, are planning a procedure to open the blocked artery, and meet safety and pregnancy criteria.
This trial studies whether starting a cholesterol-lowering medicine called a PCSK9 inhibitor early after a heart attack can improve heart health and outcomes. It focuses on people who had a recent heart-artery procedure to fix the blockage in the left anterior descending (LAD) artery.
This study tests whether a medication called a PCSK9 inhibitor (a type of drug that lowers bad cholesterol) can improve the buildup of plaque in heart arteries. It may be an option for people with coronary artery disease who have not been helped enough by statins alone.
Hear when a new Coronary Heart Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.